title: Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
abstract: While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.
authors.affiliation: Hunter Holmes McGuire VAMC, Dept. of Research and Development, Richmond VA, 23224 ( ), Virginia Commonwealth University Reanimation Engineering Science Center (VCURES), Richmond, Virginia 23298 ( ), Massey Cancer Center, Virginia Commonwealth University, Richmond VA, 23298 ( and Virginia Commonwealth University, Dept. of Biochemistry and Molecular Biology, Richmond VA, 23298 ( ).
authors.forename: L Alexis
authors.initials: LA
authors.lastname: Hoeferlin
authors.affiliation: Hunter Holmes McGuire VAMC, Dept. of Research and Development, Richmond VA, 23224 ( ), Virginia Commonwealth University Reanimation Engineering Science Center (VCURES), Richmond, Virginia 23298 ( ), Massey Cancer Center, Virginia Commonwealth University, Richmond VA, 23298 ( and Virginia Commonwealth University, Dept. of Biochemistry and Molecular Biology, Richmond VA, 23298 ( ).
authors.forename: Charles
authors.initials: C
authors.lastname: E Chalfant
authors.affiliation: Hunter Holmes McGuire VAMC, Dept. of Research and Development, Richmond VA, 23224 ( ), Virginia Commonwealth University Reanimation Engineering Science Center (VCURES), Richmond, Virginia 23298 ( ), Massey Cancer Center, Virginia Commonwealth University, Richmond VA, 23298 ( and Virginia Commonwealth University, Dept. of Biochemistry and Molecular Biology, Richmond VA, 23298 ( ).
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Park
keywords: Breast Cancer; ErbB2; Estrogen receptor; Resistance; Triple negative